DiaGenic and Ranbaxy sign marketing agreement

The DiaGenic breast cancer test offers a set of advantages over existing diagnostic methods. The use of venous blood as the test sample is both discreet and patient friendly. The DiaGenic test detects breast cancer in pre-menopausal women with good accuracy whereas mammography is problematic due to higher breast density in younger women, which obscures the mammographic image.

The commercial entry of the new breast cancer test in India was coordinated by DiaGenic’s Indian partner, PAC Med Biotech of Kolkata. All laboratory services will be undertaken in India and provided by LabIndia Instruments. The launch is scheduled within the coming months and will be available to the public at SRL Ranbaxy’s labs and collection centers throughout India.

Erik Christensen, CEO of DiaGenic, said: “We are delighted to partner with SRL Ranbaxy, which has distinguished itself as the leading diagnostics service provider in India. With a network of nearly 40 labs cum wellness centers and more than 750 collection centers across India, they will be able to ensure the test is widely accessible.”